Ignite Creation Date:
2024-05-06 @ 4:00 PM
Last Modification Date:
2024-10-26 @ 2:01 PM
Study NCT ID:
NCT04830462
Status:
COMPLETED
Last Update Posted:
2023-05-16
First Post:
2021-03-31
Brief Title:
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
Sponsor:
Herlev and Gentofte Hospital
Organization:
Herlev and Gentofte Hospital
Study Overview
Official Title:
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will be investigating the effect of latent tuberculosis infection LTBI treatment on glucose tolerance and low-grade inflammation Almost a century ago researchers proposed that diabetes DM was associated with increased risk of Tuberculosis infection TB A more recent systematic review concluded that DM increases the relative risk for TB 31 times Reversely TB may affect the glycaemic control TB is in many cases a chronic infection characterised by long term low-grade inflammation and weight loss and persons with TB are known to be at risk of hyperglycaemia and DM at time of diagnosis A latent infection with the mtuberculosis bacteria is silent without symptoms
17 billion have LTBI on a global scale Event though the infected person does not experience symptoms increased background inflammation has been shown in LTBI patients in previous studies We also know that an increase in inflammatory markers precedes clinical development of DM and that subclinical inflammation contributes to insulin resistance We hypothesise that LTBI contributes to dysregulated glucose metabolism due to increased low-grade inflammation and that treatment will reduce low-grade inflammation and improve glucose tolerance
17 billion have LTBI on a global scale Event though the infected person does not experience symptoms increased background inflammation has been shown in LTBI patients in previous studies We also know that an increase in inflammatory markers precedes clinical development of DM and that subclinical inflammation contributes to insulin resistance We hypothesise that LTBI contributes to dysregulated glucose metabolism due to increased low-grade inflammation and that treatment will reduce low-grade inflammation and improve glucose tolerance
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None